A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML.

What you commit to

• Study type: Interventional · Phase 1/2
• Planned participants: 32
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia (AML) that has come back or has not responded to treatment.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Acute myeloid leukemia that has relapsed or is refractory (did not respond to treatment).

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details